These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25385933)

  • 21. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia.
    Kader AA; Angamuthu K
    Saudi Med J; 2005 Jun; 26(6):956-9. PubMed ID: 15983682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection.
    MacVane SH; Tuttle LO; Nicolau DP
    J Hosp Med; 2014 Apr; 9(4):232-8. PubMed ID: 24464783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection.
    Lau SM; Peng MY; Chang FY
    J Microbiol Immunol Infect; 2004 Jun; 37(3):185-91. PubMed ID: 15221039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial resistance patterns of uropathogens among children in Istanbul, Turkey.
    Ipek IO; Bozaykut A; Arman DC; Sezer RG
    Southeast Asian J Trop Med Public Health; 2011 Mar; 42(2):355-62. PubMed ID: 21710858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections.
    Wu YH; Chen PL; Hung YP; Ko WC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):197-203. PubMed ID: 23063776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical analysis of 22 cases community-acquired Pseudomonas aeruginosa urinary tract infection].
    Fu XH; Zhou W; Zhang XM; Yin YB; Jing CM; Liu L; Zhao J
    Zhonghua Er Ke Za Zhi; 2013 Apr; 51(4):298-301. PubMed ID: 23927805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in a medical center in Taiwan: a prospective cohort study.
    Kung CH; Ku WW; Lee CH; Fung CP; Kuo SC; Chen TL; Lee YT
    J Microbiol Immunol Infect; 2015 Apr; 48(2):168-74. PubMed ID: 24064292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Community-onset healthcare-related urinary tract infections: comparison with community and hospital-acquired urinary tract infections.
    Aguilar-Duran S; Horcajada JP; Sorlí L; Montero M; Salvadó M; Grau S; Gómez J; Knobel H
    J Infect; 2012 May; 64(5):478-83. PubMed ID: 22285591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bacterial pathogens, resistance patterns and treatment options in community acquired pediatric urinary tract infection].
    Pape L; Gunzer F; Ziesing S; Pape A; Offner G; Ehrich JH
    Klin Padiatr; 2004; 216(2):83-6. PubMed ID: 15106080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary tract infections in children < 2 years of age hospitalized in a tertiary medical center in Southern Israel: epidemiologic, imaging, and microbiologic characteristics of first episode in life.
    Shaki D; Hodik G; Elamour S; Nassar R; Kristal E; Leibovitz R; Horev A; Leibovitz E
    Eur J Clin Microbiol Infect Dis; 2020 May; 39(5):955-963. PubMed ID: 31930442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
    Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS
    Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and laboratory profiles of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care center in central Saudi Arabia.
    Al-Otaibi FE; Bukhari EE
    Saudi Med J; 2013 Feb; 34(2):171-6. PubMed ID: 23396464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
    Vardi M; Kochavi T; Denekamp Y; Bitterman H
    Isr Med Assoc J; 2012 Feb; 14(2):115-8. PubMed ID: 22693794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections.
    Yüksel S; Oztürk B; Kavaz A; Ozçakar ZB; Acar B; Güriz H; Aysev D; Ekim M; Yalçinkaya F
    Int J Antimicrob Agents; 2006 Nov; 28(5):413-6. PubMed ID: 17000085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Childhood urinary tract infection: a clinical analysis of 597 cases.
    Wu CY; Chiu PC; Hsieh KS; Chiu CL; Shih CH; Chiou YH
    Acta Paediatr Taiwan; 2004; 45(6):328-33. PubMed ID: 15868848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria.
    Briongos-Figuero LS; Gómez-Traveso T; Bachiller-Luque P; Domínguez-Gil González M; Gómez-Nieto A; Palacios-Martín T; González-Sagrado M; Dueñas-Laita A; Pérez-Castrillón JL
    Int J Clin Pract; 2012 Sep; 66(9):891-6. PubMed ID: 22897466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First UTI episode in life in infants <1 year of age: Epidemiologic, clinical, microbiologic and disease recurrence characteristics.
    Falup-Pecurariu O; Leibovitz E; Vorovenci C; Lixandru R; Rochman F; Monescu V; Leibovitz R; Bleotu L; Falup-Pecurariu C
    Pediatr Neonatol; 2020 Dec; 61(6):613-619. PubMed ID: 32819848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotic resistance in children with recurrent or complicated urinary tract infection.
    Younis N; Quol K; Al-Momani T; Al-Awaisheh F; Al-Kayed D
    JNMA J Nepal Med Assoc; 2009; 48(173):14-9. PubMed ID: 19529052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High Rates of ESBL-producing and Gentamycin-resistant Gram-negative Bacteria During the First Week of Life: A Multicenter Cross-sectional Study Among Infants Younger Than 2 Months With Urinary Tract Infection.
    Washahi M; Miron D; Steinberg Ben Zeev Z; Chayen G; Jacob R
    Pediatr Infect Dis J; 2023 Sep; 42(9):750-753. PubMed ID: 37257122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.